CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis

Drug Dev Res. 2022 Apr;83(2):512-524. doi: 10.1002/ddr.21882. Epub 2021 Sep 19.

Abstract

Circular RNAs (circRNAs) play vital regulatory roles in the development of ovarian cancer (OC). However, the functions of circRNA Atlastin GTPase 2 (circATL2) in paclitaxel (PTX) resistance of OC are still unclear. As a result, circATL2 was upregulated in PTX-resistant OC tissues and cells. CircATL2 knockdown reduced IC50 of PTX, inhibited colony formation ability and promoted cell cycle arrest and apoptosis in PTX-resistant OC cells. Silencing of circATL2 restrained PTX resistance in vivo. Furthermore, miR-506-3p could be targeted by circATL2 and miR-506-3p inhibition reversed the impacts of circATL2 knockdown on PTX resistance and cell progression in PTX-resistant OC cells. NFIB was identified as the target of miR-506-3p. MiR-506-3p overexpression suppressed PTX resistance and malignant behaviors of PTX-resistant OC cells, with NFIB elevation rescued the impacts. To summarize, circATL2 promoted the resistance of OC to PTX by sponging miR-506-3p to upregulate NFIB expression, providing a new sight in chemoresistance of OC.

Keywords: NFIB; OC; chemoresistance; circATL2; miR-506-3p; paclitaxel.

MeSH terms

  • Drug Resistance, Neoplasm / genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • NFI Transcription Factors / genetics
  • NFI Transcription Factors / metabolism
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics
  • Paclitaxel / pharmacology

Substances

  • MIRN506 microRNA, human
  • MicroRNAs
  • NFI Transcription Factors
  • NFIB protein, human
  • Paclitaxel